Development Pipeline
PF-655
QPI-1002
QPI-1007
Program for Pipeline siRNAs
Disease Indications
Letter from the CEO
Company Profile
Management
Board of Directors
Mission, Vision and Values
Licensing Partners
News
Careers
Website Disclaimer
Overview
News
Overview
Current Collaborations
ClinicalStudies
SiRNA
Intellectual Property
About Us
Product Candidates
Research & Development
Investor Relations
Contact
Development Pipeline
PF-655
QPI-1002
QPI-1007
Program for Pipeline siRNAs
Disease Indications
Letter from the CEO
Company Profile
Management
Board of Directors
Mission, Vision and Values
Licensing Partners
News
Careers
Website Disclaimer
Overview
News
Overview
Current Collaborations
ClinicalStudies
SiRNA
Intellectual Property
About Us
Product Candidates
Research & Development
Investor Relations
Contact
1/4/2012
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007
Read More>
2012
2011
2010
2009
2008
2007
2006
2005
Home
Products
Contact
©2007 Quark Pharmaceuticals, Inc.